Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

In the past decade clinical and laboratory studies have led to important new insights into the
biology of chronic myeloid leukemia (CML). Basic science has defined the molecular …

The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

Background Resistance to imatinib mesylate can occur in chronic myelogenous leukemia
(CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL …

Purpose Deep molecular response (MR4. 5) defines a subgroup of patients with chronic
myeloid leukemia (CML) who may stay in unmaintained remission after treatment …

Chronic myeloid leukaemia (CML) was the first neoplastic disease for which knowledge of
the genotype led to a rationally designed therapy. As a result of its well known …

Nilotinib, an orally bioavailable, selective Bcr-Abl tyrosine kinase inhibitor, is 30-fold more
potent than imatinib in pre-clinical models, and overcomes most imatinib resistant BCR-ABL …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Using high-performance liquid chromatography–tandem mass spectrometry, we assessed
trough imatinib plasma levels in 68 patients with chronic myeloid leukemia (CML) who …

Purpose Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400
mg/d can be unsatisfactory. Optimization of treatment is warranted. Patients and Methods In …